Background: Alloimmunization to red blood cells (RBCs) presents a significant challenge in blood transfusion for individuals afflicted with sickle cell disease (SCD) and thalassemia. However, there is a scarcity of data regarding the prevalence of RBC alloimmunization in such patients in Saudi Arabia. To address this gap, a comprehensive meta-analysis was undertaken to ascertain the rate of RBC alloimmunization in SCD and thalassemia patients who receive regular transfusions in Saudi Arabia.
Methods: A systematic search and subsequent meta-analysis, following PRISMA guidelines, were carried out. We meticulously combed through six prominent scientific databases, including PubMed, Web of Science, SCOPUS, EMBASE, MEDLINE, and Google Scholar, up to July 20, 2023, to identify pertinent English-language articles. Data were meticulously extracted from the selected studies. The meta-analysis adopted a random-effects model and included subgroup analyses to delineate the RBC alloimmunization rates specifically for SCD and thalassemia patients receiving regular transfusions. Heterogeneity was assessed through Cochran's Q and I2 tests. The study protocol was registered under PROSPERO, with the code CRD42023440761.
Results: Our comprehensive search yielded a total of 983 articles, with 12 meeting the criteria for the final analysis, encompassing a total of 1,811 SCD and thalassemia patients. The collective RBC alloimmunization rate across all the eligible articles for patients with SCD and thalassemia who received regular transfusions in Saudi Arabia was determined to be 18.2%. Subgroup analysis, comprising nine articles, indicated that the RBC alloimmunization rate among SCD patients was 18.6%, while analysis of six articles revealed that the rate among thalassemia patients stood at 19.5%.
Conclusions: This meta-analysis underscores that the RBC alloimmunization rate in SCD and thalassemia patients who regularly receive transfusions in Saudi Arabia stands at 18.2%. Considering these findings, it is essential to prioritize extended phenotyping prior to transfusion to significantly reduce the risk of RBC alloimmunization.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7754/Clin.Lab.2024.240827 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Alloimmunization to red blood cells (RBCs) presents a significant challenge in blood transfusion for individuals afflicted with sickle cell disease (SCD) and thalassemia. However, there is a scarcity of data regarding the prevalence of RBC alloimmunization in such patients in Saudi Arabia. To address this gap, a comprehensive meta-analysis was undertaken to ascertain the rate of RBC alloimmunization in SCD and thalassemia patients who receive regular transfusions in Saudi Arabia.
View Article and Find Full Text PDFTwo Nonmyeloablative HLA-Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Regimens in Patients with Severe Sickle Cell Disease.
Transplant Cell Ther
February 2025
Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Nonmyeloablative (NMA) conditioning is being used increasingly with success in matched related donor (MRD) and alternative donor allogeneic hematopoietic cell transplantation (allo-HCT) in individuals with sickle cell disease (SCD). Advantages include decrease toxicity and applicability in patients otherwise unable to tolerate conditioning regimens due to end-organ damage or age. We aimed to add to published data outcomes of two similar NMA conditioning protocols, termed Protocol 1 (ClinicalTrials.
View Article and Find Full Text PDFExtended Typing of Common Erythrocyte Antigens in Tunisian Blood Donors and Its Usefulness in Transfusion Immunology.
Int J Immunogenet
February 2025
Research Laboratory (LR20SP05), Department of Immunohaematology; National Blood Transfusion Centre of Tunis, University of Tunis El Manar, Tunis, Tunisia.
Extended RBC antigens typing is very valuable in transfusion immunology since it is highly recommended to ensure better transfusion practices and avoid transfusion-related complications and to establish registries for rare blood donors as recommended by the International Society of Blood Transfusion and World Health Organization. A group of 236 Tunisian blood donors were genotyped for 19 common blood loci using the Sequence-specific primers polymerase chain reaction (SSP-PCR) method. The statistical analysis was done using the HaploView Software.
View Article and Find Full Text PDFEarly alloimmunization in an infant to red cell antigens-Rare but possible in the 'right' circumstances.
Transfus Med
February 2025
New Zealand Blood Service, Christchurch, New Zealand.
Background: Red blood cell (RBC) alloimmunization is rarely reported in infants less than 4-6 months of age.
Methods/materials: Blood group and antibody screening used the gel card technique. All blood products were leukoreduced.
Platelet Additive Solutions and Pathogen Reduction Impact on Transfusion Safety, Patient Management and Platelet Supply.
Transfus Med Rev
January 2025
French National Agency for Medicines and Health Products Safety (ANSM), Saint Denis, France.
Since 1998, leuko-reduction is used in France for all platelet concentrates (PCs), apheresis-derived (APCs) and pooled whole blood-derived buffy-coats (BCPCs). Platelet additive solutions (PAS), introduced in 2005, accounted for over 80% of the platelet supply from 2011 to 2017. The Intercept pathogen reduction technology (PR), started in a pilot study in 2007, was generalized in 2018.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!